Sun Pharma

The cost of acquisition is about $8.2 million

The company's focus is also on supply chain protection and ensuring optimum utilisation of its factories informed the MD of the…

ILUMYA is one of the key specialty products of Sun Pharma and it was approved by US FDA in March 2018 while the European…

ILUMYA (tildrakizumab) is an US FDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with…

Analyses of long-term data confirm that the continued and clinically meaningful results of ODOMZO (sonidegib) in people with…

Reportedly, updated cost analysis reveals ILUMYA is among the most cost-effective first-line treatments for moderate-to-severe…

Attorney General Brian E Frosh in a statement issued on Wednesday said the new complaint, filed in the U.S. District Court for the…

AQCH is the first phytopharmaceutical drug approved for clinical trial by DCGI for COVID-19 and has shown anti-SARS-CoV-2 effects…

Nafamostat is identified as a potential candidate for COVID-19 patients by scientists at the University of Tokyo and Leibniz…

It is a potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders